(Unaudited data)
· Cumulative activity as of the end of december 2015
| thousands of euros | 2014 | 2015 | Variation at current exchange rates | Variation at constant exchange rates |
| France | 343,891 | 361,765 | +5.2% | +5.2% |
| Europe (excluding France) | 198,918 | 167,714 | -15.7% | -11.9% |
| North America | 52,813 | 63,858 | +20.9% | +3.8% |
| Other countries | 14,126 | 14,466 | +2.4% | +5.7% |
| Group total | 609,748 | 607,803 | -0.3% | -0.5% |
| thousands of euros | 2014 | 2015 | Variation at current exchange rates | Variation at constant exchange rates |
| Non-proprietary Homeopathic Medicines | 305,501 | 310,555 | +1.7% | +0.8% |
| OTC Specialties | 303,549 | 296,954 | -2.2% | -1.7% |
| Other | 698 | 294 | -57.9% | -37.7% |
| Group total | 609,748 | 607,803 | -0.3% | -0.5% |
· Quarterly activity in 2015 ( variation at current rate)
|
thousands of euros |
1 st quarter |
2 nd quarter |
3 rd quarter |
4 th quarter |
||||||||
|
2014 |
2015 |
Var. 15/14 |
2014 |
2015 |
Var. 15/14 |
2014 |
2015 |
Var. 15/14 |
2014 |
2015 |
Var. 15/14 |
|
|
France |
82,749 |
89,584 |
+8.3% |
74,269 |
76,864 |
+3.5% |
92,466 |
97,767 |
+5.7% |
94,407 |
97,550 |
+3.3% |
|
Europe (excluding France) |
39,967 |
40,657 |
+1.7% |
33,570 |
29,943 |
-10.8% |
62,758 |
50,614 |
-19.4% |
62,623 |
46,500 |
-25.7% |
|
North America |
12,662 |
17,193 |
+35.8% |
10,625 |
12,894 |
+21.4% |
13,109 |
16,055 |
+22.5% |
16,417 |
17,716 |
+7.9% |
|
Other countries |
4,831 |
4,622 |
-4.3% |
2,943 |
3,816 |
+29.7% |
3,779 |
3,594 |
-4.9% |
2,573 |
2,434 |
-5.4% |
|
Group total |
140,209 |
152,056 |
+8.4% |
121,407 |
123,517 |
+1.7% |
172,112 |
168,030 |
-2.4% |
176,020 |
164,200 |
-6.7% |
|
thousands of euros |
1 st quarter |
2 nd quarter |
3 rd quarter |
4 th quarter |
||||||||
|
2014 |
2015 |
Var. 15/14 |
2014 |
2015 |
Var. 15/14 |
2014 |
2015 |
Var. 15/14 |
2014 |
2015 |
Var. 15/14 |
|
|
Non-proprietary Homeopathic Medicines |
77,919 |
79,191 |
+1.6% |
73,072 |
74,354 |
+1.8% |
72,957 |
73,677 |
+1.0% |
81,553 |
83,333 |
+2.2% |
|
OTC Specialties |
62,196 |
72,880 |
+17.2% |
48,058 |
49,030 |
+2.0% |
99,025 |
94,328 |
-4.7% |
94,270 |
80,716 |
-14.4% |
|
Other |
94 |
-15 |
- |
277 |
133 |
-52.0% |
130 |
25 |
-80.8% |
197 |
151 |
-23.4% |
|
Group total |
140,209 |
152,056 |
+8.4% |
121,407 |
123,517 |
+1.7% |
172,112 |
168,030 |
-2.4% |
176,020 |
164,200 |
-6.7% |
Highlights of the fourth quarter
Sales revenue of the fourth quarter 2015 was down by 6.7% (-6.4% at constant rate). Such decrease mainly results from the situation in Russia.
Thus, the 2015 operating income will be lower than in 2014.
On December 22, 2015, our company has set up a new subsidiary in India and thus confirms its involvement in the development of homeopathy in the world.
Our next update: March 16, 2016, after the close of the stock market, publication of 2015 results.
Person responsible for financial information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information is online at: www.boironfinance.com
Information réglementée
Communiqués au titre de l'obligation d'information permanente :
- Communiqué sur comptes, résultats, chiffres d'affaires
Full and original press release in PDF:
http://www.actusnews.com/documents_communiques/ACTUS-0-42839-BOI-210116-CA-15-GB.pdf
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer